HAL will be down for maintenance from Friday, June 10 at 4pm through Monday, June 13 at 9am. More information
Skip to Main content Skip to Navigation
Book section

Cell-free DNA in the management of colorectal cancer

Abstract : Colorectal cancer is one of the leading cause of death by cancer worldwide in both men and women. Liquid biopsy belongs nowadays to the landscape of cancer management biological tools. In this chapter, we will describe and discuss the actual, potential and future applications of cfDNA analysis in plasma of patients with colorectal cancer in early or metastatic stage. During the last decade, the development of molecular biology assays like digital PCR or next-generation sequencing made the analysis of cfDNA in plasma possible with an excellent sensitivity and applications like early detection, diagnosis, prognosis, response to treatment, monitoring of an emerging resistance, mapping of the disease molecular landscape or evaluation of the residual disease are now feasible. cfDNA detection has several promising applications in the management of patients with colorectal cancer, but prospective randomised clinical trials are still lacking to make liquid biopsy ready for prime-time.
Document type :
Book section
Complete list of metadata

Contributor : Alexandre Harlé Connect in order to contact the contributor
Submitted on : Tuesday, October 22, 2019 - 10:43:42 AM
Last modification on : Wednesday, November 3, 2021 - 8:09:32 AM




Alexandre Harlé. Cell-free DNA in the management of colorectal cancer. Florence Schaffner, Jean-Louis Merlin et Nikolas von Bubnoff. Tumor Liquid Biopsies, 215, Springer, pp.253-261, 2020, Recent Results in Cancer Research, 978-3-030-26438-3. ⟨10.1007/978-3-030-26439-0_13⟩. ⟨hal-02325084⟩



Record views